Societe Internationale d'Oncologie Pediatrique (SIOP)   Report issue

Academic/Hospital Phase 2 Phase 3
Founded: Paris France (1967)

Organization Overview

First Clinical Trial
1992
NCT00003859
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2004

Timeline

NOW
  • Now

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Central Nervous System Neoplasms (Phase 3)

Ependymoma (Phase 2)

Glioma (Phase 3)

Hepatoblastoma (Phase 3)

Histiocytoma (Phase 3)

Histiocytoma, Benign Fibrous (Phase 3)

Histiocytoma, Malignant Fibrous (Phase 3)

Intestinal Neoplasms (Phase 2)

Liver Neoplasms (Phase 3)

Nervous System Neoplasms (Phase 3)

Neuroblastoma (Phase 3)

Neuroectodermal Tumors (Phase 3)

Neuroectodermal Tumors, Primitive (Phase 3)

Rhabdomyosarcoma (Phase 3)

Sarcoma (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 8
  • # of Trial APIs: 11